Stock Markets January 23, 2026

Kepler Cheuvreux Reinforces Relx Buy Rating, Eyes AI-Driven Revenue Growth

Broker highlights growing AI benefits in legal and scientific segments amid valuation pullback

By Hana Yamamoto
Kepler Cheuvreux Reinforces Relx Buy Rating, Eyes AI-Driven Revenue Growth

Kepler Cheuvreux has upgraded Relx to its Sector Most Preferred List, maintaining a buy rating with a target price of 3,905 pence. The broker attributes recent share price declines to overblown concerns about AI disruption, instead emphasizing AI-driven growth opportunities in Relx's legal and scientific divisions. Revenue and margin forecasts for the next two years were raised, underpinned by innovative AI product launches and steady subscription models.

Key Points

  • Kepler Cheuvreux includes Relx in Sector Most Preferred List with buy rating and price target of 3,905 pence.
  • Increased organic revenue growth forecasts to 6.1% for 2026 and 6.2% for 2027 due to AI-driven advancements and reduced federal funding risk in STM division.
  • Legal revenues now feature 60% from analytics, showing accelerated growth aided by new AI platform Protégé General AI.
  • AI implementation has led to cost efficiencies with unit costs down and 30% of new code generated by AI, boosting productivity by 20-30%. Potential launch of LeapSpace AI-powered platform scheduled for early 2026 in STM sector.

Kepler Cheuvreux has included Relx on its Sector Most Preferred List, while reaffirming a buy recommendation and setting a target price at 3,905 pence. This move follows a stock price retreat driven by investor anxieties over potential disruptions from artificial intelligence (AI), which the broker now deems excessive.

Despite a significant valuation contraction observed in 2025, Relx's decline was notably less severe than that experienced by peer Wolters Kluwer, as evidence mounts that AI initiatives are accelerating growth rather than undermining business fundamentals.

The brokerage increased its projected organic revenue growth estimates, adjusting to 6.1% for 2026 and 6.2% for 2027 from prior forecasts of 5.9% and 6.0%, respectively. These upgrades were bolstered by reduced risks related to U.S. federal funding within Relx's Scientific, Technical & Medical (STM) segment.

Likewise, margin forecasts were improved to 35% in 2026 and 34.9% in 2027, driven by optimistic outlooks in both STM and Exhibitions divisions, as detailed in Kepler's January 22 report.

Investor concerns have concentrated on AI's potential to disrupt Relx's Legal and STM arms, especially in areas such as research discovery. Nevertheless, Kepler pointed out concrete advancements generated by AI applications in Legal, which has progressed to third-generation AI products.

Approximately 60% of Legal division revenues now derive from analytics, a substantial increase from 20% recorded in 2021. This segment's like-for-like revenue growth has accelerated to about 8%, markedly improving upon the roughly 2% growth observed before the pandemic.

Relx's latest offering, the Protégé General AI platform launched in the fourth quarter of 2025, integrates LexisNexis+ AI and Protégé solutions into a unified system. It utilizes 14 third-party AI models and adopts a language-model-agnostic framework introduced early in 2023, ahead of competitors by around 18 months.

These AI-driven enhancements have propelled consistent double-digit rises in average client spending, with pricing strategies focused on value and contracts typically spanning three years. Multi-year subscriptions account for about 85% of Legal revenues, facilitating gradual growth as renewals occur at increased price points.

Kepler noted that AI deployment has not substantially increased costs; instead, unit costs are decreasing. The cost per large language model (LLM) transaction dropped 24% year-on-year, while an estimated 30% of new code is now generated by AI, yielding productivity improvements estimated between 20% and 30%.

In the STM sector, Relx plans to debut LeapSpace, a comprehensive AI-powered research platform, in the first quarter of 2026. This platform builds on ScienceDirect AI and Scopus AI foundations and accesses a knowledge base exceeding 100 million records and 15 million peer-reviewed articles. LeapSpace will replace ScienceDirect AI for existing customers automatically.

The Risk division demonstrates resilient performance, with over 90% of its revenues stemming from machine-to-machine solutions embedded in client workflows. High switching costs and strong customer retention underscore this division's stability.

Relx has confirmed its full-year 2025 guidance, forecasting around 7% like-for-like revenue growth. The company, with a market capitalization near £54 billion, trades at approximately 20.9 times forecasted earnings for 2026, representing a 15% to 20% discount relative to Wolters Kluwer. Free cash flow is projected at £2.75 billion for 2026, implying a yield of roughly 5.2%, alongside a forecast dividend yield of 2.4%.

Risks

  • Investor concerns around AI disruption in Legal and STM divisions, particularly regarding research discovery, may continue to affect valuation and investor sentiment.
  • Dependency on multi-year subscription renewals in Legal revenues means growth is gradual and could be impacted by subscription retention challenges.
  • U.S. federal funding risk reduction noted, but any resurgence in funding uncertainty could affect the Scientific, Technical & Medical division's revenue projections.

More from Stock Markets

January jobs report postponed amid partial federal funding lapse Feb 2, 2026 Wave Life Sciences Reclaims Full Rights to AATD Candidate, Stock Edges Higher Feb 2, 2026 U.K. Stocks Close Higher as United Kingdom 100 Hits Record High Feb 2, 2026 U.K. Stocks Climb as United Kingdom 100 Reaches Record High; Travel and Leisure Names Lead Gains Feb 2, 2026 Spanish Stocks Close Higher as IBEX 35 Hits Record High Feb 2, 2026